肝细胞癌分子异质性与临床精准治疗

邹强; 王军; 文良志; 王斌; 张毅

doi:10.3969/j.issn.1001-5256.2021.08.006

肝细胞癌分子异质性与临床精准治疗

DOI: 10.3969/j.issn.1001-5256.2021.08.006

邹强^{1, 2},
王军¹,
文良志¹,
王斌^1, ,,
张毅^2, ,

1.
陆军军医大学大坪医院消化内科，重庆 400042
2.
重庆大学附属肿瘤医院肝胆胰肿瘤科，重庆 400042

基金项目:

国家自然科学基金项目 (81872027);

国家自然科学基金项目 (82002585);

陆军军医大学科研项目 (2019XQY19)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：邹强负责拟定写作思路，文献搜集和分析，撰写论文并绘图；王军、文良志参与文献搜集，指导撰写文章，修改论文；王斌、张毅负责拟定写作主题，修改论文并最后定稿。

详细信息

通信作者:
王斌，wb_tmmu@126.com

张毅，zhangyi9611@sina.com

中图分类号: R735.7
计量
- 文章访问数: 813
- HTML全文浏览量: 166
- PDF下载量: 176
- 被引次数: 0
出版历程
- 收稿日期: 2021-05-28
- 录用日期: 2021-05-28
- 出版日期: 2021-08-20

Molecular heterogeneity of hepatocellular carcinoma and its precise treatment in clinical practice

Qiang ZOU^{1, 2},
Jun WANG¹,
Liangzhi WEN¹,
Bin WANG^{1
, ,},
Yi ZHANG^{2
, ,}

1.
Department of Gastroenterology, Daping Hospital, Army Medical University, Chongqing 400042, China
2.
Department of Hepatobiliary Surgery, Chongqing University Cancer Hospital, Chongqing 400042, China

Research funding:

National Natural Science Foundation of China (81872027);

National Natural Science Foundation of China (82002585);

Scientific Research Project of Army Medical University (2019XQY19)

摘要

摘要: 肝细胞癌是我国最常见的肝癌类型，分子异质性显著，极大地制约了临床疗效，因此深入探索其异质性的分子分型，对于制订个体化诊疗策略极为重要。近年来多种高通量测序技术层出不穷，结合多组学特征提出了多种分子分型系统，使临床研究者对肝癌分子异质性有了更加深刻的认识。详细总结了肝细胞癌的分子分型，探讨其与临床病理特征的密切联系，分析分子靶向治疗和免疫治疗的干预新靶标，提出了肝癌精准诊断和个体化治疗的新思路。
- 癌，肝细胞 /
- 遗传异质性 /
- 治疗学
Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer in China, and high molecular heterogeneity of HCC has caused the limitations in clinical efficacy; therefore, it is of great importance to explore its heterogeneity based on molecular classification and develop individualized diagnosis and treatment strategies. Various high-throughput sequencing techniques and multi-omics techniques in recent years have helped to establish multiple molecular classification systems, which gives us a deeper understanding of the molecular heterogeneity of HCC. This article summarizes the molecular classifications of HCC and discusses their association with clinicopathological features. This article also analyzes the new targets for molecular targeted therapy and immunotherapy and proposes new ideas for precise diagnosis and individualized treatment of HCC.
- Carcinoma, Hepatocellular /
- Genetic Heterogeneity /
- Therapeutics

HTML全文

图 1 2004—2020年间基于基因组、转录组、蛋白质组、代谢特征和免疫特征研究发表的HCC分子亚型

下载: 全尺寸图片幻灯片

参考文献(40)

[1]	CRAIG AJ, VON FELDEN J, GARCIA-LEZANA T, et al. Tumour evolution in hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(3): 139-152. DOI: 10.1038/s41575-019-0229-4.
[2]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[3]	BRUIX J, REIG M, SHERMAN M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4): 835-853. DOI: 10.1053/j.gastro.2015.12.041.
[4]	WU Y, LIU Z, XU X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine[J]. Cancer Commun (Lond), 2020, 40(12): 681-693. DOI: 10.1002/cac2.12115.
[5]	GONG J, CHEHRAZI-RAFFLE A, REDDI S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations[J]. J Immunother Cancer, 2018, 6(1): 8. DOI: 10.1186/s40425-018-0316-z.
[6]	LLOVET JM, ZUCMAN-ROSSI J, PIKARSKY E, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2016, 2: 16018. DOI: 10.1038/nrdp.2016.18.
[7]	LLOVET JM, BRU' C, BRUIX J. Prognosis of hepatocellular carcinoma: The BCLC staging classification[J]. Semin Liver Dis, 1999, 19(3): 329-338. DOI: 10.1055/s-2007-1007122.
[8]	BANNASCH P, RIBBACK S, SU Q, et al. Clear cell hepatocellular carcinoma: Origin, metabolic traits and fate of glycogenotic clear and ground glass cells[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(6): 570-594. DOI: 10.1016/S1499-3872(17)60071-7.
[9]	FAIVRE S, RIMASSA L, FINN RS. Molecular therapies for HCC: Looking outside the box[J]. J Hepatol, 2020, 72(2): 342-352. DOI: 10.1016/j.jhep.2019.09.010.
[10]	ERSTAD DJ, FUCHS BC, TANABE KK. Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy[J]. Cancer, 2018, 124(15): 3084-3104. DOI: 10.1002/cncr.31257.
[11]	CHIANG DY, VILLANUEVA A, HOSHIDA Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma[J]. Cancer Res, 2008, 68(16): 6779-6788. DOI: 10.1158/0008-5472.CAN-08-0742.
[12]	SCHULZE K, IMBEAUD S, LETOUZÉ E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets[J]. Nat Genet, 2015, 47(5): 505-511. DOI: 10.1038/ng.3252.
[13]	FUJIMOTO A, FURUTA M, TOTOKI Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer[J]. Nat Genet, 2016, 48(5): 500-509. DOI: 10.1038/ng.3547.
[14]	LEE JS, CHU JS, CHU IS, HEO J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling[J]. Hepatology, 2004, 40(3): 667-676. DOI: 10.1002/hep.20375.
[15]	JIANG X, KIM HE, SHU H, et al. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway[J]. Science, 2003, 299(5604): 223-226. DOI: 10.1126/science.1076807.
[16]	SEMENZA GL. Targeting HIF-1 for cancer therapy[J]. Nat Rev Cancer, 2003, 3(10): 721-732. DOI: 10.1038/nrc1187.
[17]	LEE JS, HEO J, LIBBRECHT L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells[J]. Nat Med, 2006, 12(4): 410-416. DOI: 10.1038/nm1377.
[18]	BOYAULT S, RICKMAN DS, de REYNIÈS A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets[J]. Hepatology, 2007, 45(1): 42-52. DOI: 10.1002/hep.21467.
[19]	HOSHIDA Y, NIJMAN SM, KOBAYASHI M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma[J]. Cancer Res, 2009, 69(18): 7385-7392. DOI: 10.1158/0008-5472.CAN-09-1089.
[20]	ZAVADIL J, BÖTTINGER EP. TGF-beta and epithelial-to-mesenchymal transitions[J]. Oncogene, 2005, 24(37): 5764-5774. DOI: 10.1038/sj.onc.1208927.
[21]	GIANNELLI G, BERGAMINI C, FRANSVEA E, et al. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma[J]. Gastroenterology, 2005, 129(5): 1375-1383. DOI: 10.1053/j.gastro.2005.09.055.
[22]	HOPPLER S, KAVANAGH CL. Wnt signalling: Variety at the core[J]. J Cell Sci, 2007, 120(Pt 3): 385-393. DOI: 10.1242/jcs.03363.
[23]	MUTO Y, MORIWAKI H, SHIRATORI Y. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma[J]. Digestion, 1998, 59(Suppl 2): 89-91. DOI: 10.1159/000051435.
[24]	ZHANG Y, WANG G, MA W, et al. CdS p-n heterojunction co-boosting with Co(3)O(4) and Ni-MOF-74 for photocatalytic hydrogen evolution[J]. Dalton Trans, 2018, 47(32): 11176-11189. DOI: 10.1039/c8dt02294a.
[25]	HANAHAN D, WEINBERG RA. Hallmarks of cancer: The next generation[J]. Cell, 2011, 144(5): 646-674. DOI: 10.1016/j.cell.2011.02.013.
[26]	DÉSERT R, ROHART F, CANAL F, et al. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection[J]. Hepatology, 2017, 66(5): 1502-1518. DOI: 10.1002/hep.29254.
[27]	YANG C, HUANG X, LIU Z, et al. Metabolism-associated molecular classification of hepatocellular carcinoma[J]. Mol Oncol, 2020, 14(4): 896-913. DOI: 10.1002/1878-0261.12639.
[28]	SHANKARAIAH RC, CALLEGARI E, GUERRIERO P, et al. Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma[J]. Oncogene, 2019, 38(45): 7035-7045. DOI: 10.1038/s41388-019-0942-z.
[29]	DUFFY AG, ULAHANNAN SV, MAKOROVA-RUSHER O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3): 545-551. DOI: 10.1016/j.jhep.2016.10.029.
[30]	EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
[31]	KILLOCK D. Immunotherapy: Nivolumab keeps HCC in check and opens avenues for checkmate[J]. Nat Rev Clin Oncol, 2017, 14(7): 392. DOI: 10.1038/nrclinonc.2017.70.
[32]	JIANG Y, SUN A, ZHAO Y, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma[J]. Nature, 2019, 567(7747): 257-261. DOI: 10.1038/s41586-019-0987-8.
[33]	GAO Q, ZHU H, DONG L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma[J]. Cell, 2019, 179(2): 561-577. e22. DOI: 10.1016/j.cell.2019.08.052.
[34]	SIA D, JIAO Y, MARTINEZ-QUETGLAS I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features[J]. Gastroenterology, 2017, 153(3): 812-826. DOI: 10.1053/j.gastro.2017.06.007.
[35]	KUREBAYASHI Y, OJIMA H, TSUJIKAWA H, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification[J]. Hepatology, 2018, 68(3): 1025-1041. DOI: 10.1002/hep.29904.
[36]	KIM HD, SONG GW, PARK S, et al. Association between expression level of PD1 by tumor-infiltrating CD8⁺T cells and features of hepatocellular carcinoma[J]. Gastroenterology, 2018, 155(6): 1936-1950. e17. DOI: 10.1053/j.gastro.2018.08.030.
[37]	ZHANG Q, LOU Y, YANG J, et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas[J]. Gut, 2019, 68(11): 2019-2031. DOI: 10.1136/gutjnl-2019-318912.
[38]	LIM HY, HEO J, CHOI HJ, et al. A phase Ⅱ study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20(23): 5976-5985. DOI: 10.1158/1078-0432.CCR-13-3445.
[39]	HO DWH, CHAN LK, CHIU YT, et al. TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication[J]. Gut, 2017, 66(8): 1496-1506. DOI: 10.1136/gutjnl-2016-312734.
[40]	SUN W, LI SC, XU L, et al. High FLT3 levels may predict sorafenib benefit in hepatocellular carcinoma[J]. Clin Cancer Res, 2020, 26(16): 4302-4312. DOI: 10.1158/1078-0432.CCR-19-1858.